When timely angioplasty is unavailable to older ST-segment elevation myocardial infarction (STEMI) patients, a modified pharmaco-invasive reperfusion strategy could be reasonable, according to the ...

NEW ORLEANS, LA—When timely primary PCI is not possible, a pharmacoinvasive strategy of half-dose tenecteplase may provide a safe and effective reperfusion alternative in older patients with STEMI, ...

Giving half-dose thrombolytic to ST-elevation myocardial infarction (STEMI) patients who are going to have a delay in receiving primary percutaneous coronary intervention (PCI), provided effective ...

Please provide your email address to receive an email when new articles are posted on . The study examined 458 adults given IV tenecteplase or placebo 4.5 to 24 hours after stroke. At 90 days after ...

Please provide your email address to receive an email when new articles are posted on . Tenecteplase was noninferior to alteplase for acute ischemic stroke when given within 4.5 hours of symptom onset ...

Intravenous (IV) tenecteplase works just as well as IV alteplase in patients with large-vessel occlusion (LVO) stroke who are eligible for thrombolysis, new research shows. In a prespecified secondary ...

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...

NEW ORLEANS -- IV tenecteplase (TNKase) could be beneficial as far out as 24 hours after stroke onset in people not getting mechanical thrombectomy, the OPTION trial showed. In people with acute ...

LOS ANGELES, CA—Bumping up the dose of tenecteplase used in patients with large-vessel-occlusion (LVO) strokes who are scheduled for endovascular thrombectomy does not improve cerebral reperfusion or ...